CN1539496A - 治疗皮肤损伤的外用药物组合物 - Google Patents
治疗皮肤损伤的外用药物组合物 Download PDFInfo
- Publication number
- CN1539496A CN1539496A CNA200410029549XA CN200410029549A CN1539496A CN 1539496 A CN1539496 A CN 1539496A CN A200410029549X A CNA200410029549X A CN A200410029549XA CN 200410029549 A CN200410029549 A CN 200410029549A CN 1539496 A CN1539496 A CN 1539496A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- skin
- treatment
- flos
- lupuli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 44
- 229940079593 drug Drugs 0.000 title description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 11
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 9
- 206010067197 Tinea manuum Diseases 0.000 claims abstract description 7
- 201000004647 tinea pedis Diseases 0.000 claims abstract description 7
- 208000006934 radiodermatitis Diseases 0.000 claims abstract description 5
- 206010031252 Osteomyelitis Diseases 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims description 71
- 208000025865 Ulcer Diseases 0.000 claims description 27
- 239000002674 ointment Substances 0.000 claims description 26
- 231100000397 ulcer Toxicity 0.000 claims description 24
- 206010063562 Radiation skin injury Diseases 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 17
- 230000036285 pathological change Effects 0.000 claims description 14
- 231100000915 pathological change Toxicity 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 6
- 206010041303 Solar dermatitis Diseases 0.000 claims description 6
- 201000010618 Tinea cruris Diseases 0.000 claims description 6
- 206010048222 Xerosis Diseases 0.000 claims description 6
- 210000002683 foot Anatomy 0.000 claims description 6
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 6
- 230000009759 skin aging Effects 0.000 claims description 6
- 208000012641 Pigmentation disease Diseases 0.000 claims description 5
- 230000019612 pigmentation Effects 0.000 claims description 5
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 206010048946 Anal abscess Diseases 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 206010012444 Dermatitis diaper Diseases 0.000 claims 2
- 208000003105 Diaper Rash Diseases 0.000 claims 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 6
- 239000000969 carrier Substances 0.000 abstract description 3
- 235000013405 beer Nutrition 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229930003270 Vitamin B Natural products 0.000 description 22
- 235000019156 vitamin B Nutrition 0.000 description 22
- 239000011720 vitamin B Substances 0.000 description 22
- 230000035876 healing Effects 0.000 description 21
- 208000028990 Skin injury Diseases 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 230000006378 damage Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 206010040943 Skin Ulcer Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 230000005855 radiation Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 231100000019 skin ulcer Toxicity 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000019155 Radiation injury Diseases 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000003908 antipruritic agent Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- -1 nucleic acid compound Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 210000003371 toe Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003026 cod liver oil Substances 0.000 description 4
- 235000012716 cod liver oil Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 229960004919 procaine Drugs 0.000 description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 208000024779 Comminuted Fractures Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010011684 Cutaneous tuberculosis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical class [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010036410 Postoperative wound infection Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000006067 antibiotic powder Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZGRKFKYTCMLCCF-UHFFFAOYSA-N cobalt;oxalonitrile Chemical compound [Co].N#CC#N ZGRKFKYTCMLCCF-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000429 cutaneous necrosis Toxicity 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 201000010098 pleural tuberculosis Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical compound [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
Description
组别 | 剂量(g) | 动物数(只) | 愈合时间(d) | 愈合速度(mm2/d) |
治疗组 | 1.0 | 14 | 18.64±1.22 | 18.57±2.02 |
对照组 | 1.0 | 14 | 22.70±1.73 | 14.86±2.60 |
模型组 | - | 7 | 30.57±1.72 | 10.57±1.81 |
组别 | 剂量(g) | 动物数(只) | RNA(μg/100g) |
治疗组 | 1.0 | 7 | 518.6±12.70 |
对照组 | 1.0 | 7 | 324.1±34.20 |
模型对照 | - | 7 | 188.7±2.37 |
空白对照 | - | 7 | 517.6±7.13 |
组别 | 剂量(g) | 基础阈值 | 药前痛阈 | 药后30min | 药后60min | 药后90min |
治疗组 | 1.0 | 45.5±2.01 | 32.5±1.72ΔΔΔ | 38.1±2.02*** | 35.1±1.52** | 44.8±1.62*** |
0.5 | 44.8±1.69 | 32.1±2.02ΔΔΔ | 36.2±2.44*** | 35.8±1.93** | 39.5±2.46*** | |
普鲁卡因 | 0.5 | 44.3±2.21 | 31.7±1.77ΔΔΔ | 37.8±2.04*** | 38.6±2.9** | 40.9±2.13*** |
基质 | 1.0 | 44.2±1.62 | 31.6±2.50ΔΔΔ | 30.0±2.11 | 29.7±2.21 | 28.9±1.91 |
模型 | - | 44.1±2.47 | 31.5±1.96ΔΔΔ | 30.4±2.99 | 30.8±1.99 | 30.6±2.41 |
组别 | 例数 | 治愈 | 显效 | 有效 | 无效 | 愈合天数 | 总有效率% |
治疗组 | 307 | 220 | 30 | 30 | 27 | 26.46±5.06 | 91.2 |
对照组 | 100 | 50 | 4 | 6 | 40 | 38.64±8.47 | 60.0 |
组别 | 例数 | 完全缓解 | 缓解时间 | 未全缓解 | 未缓解时间 |
治疗组 | 196 | 183 | 38 | 13天 | >5天 |
烧烫宁乳膏 | 50 | 0 | 0 | 50天 | 同上 |
啤酒花浸膏 | 64 | 0 | 0 | 64天 | 同上 |
例数 | 年龄 | 治愈 | 好转 | 无效 | 用时(天) | 总有效率 | |
治疗组 | 51 | 48.7 | 46 | 3 | 2 | 31.4±12.25 | 96.07% |
对照组 | 30 | 45.8 | 9 | 6 | 15 | 60.1±20.20 | 50.00% |
例数 | 年龄 | 治愈 | 好转 | 无效 | 用时(天) | 总有效率 | |
治疗组 | 102 | 68.9 | 94 | 2 | 6 | 37.9±10.73 | 94.11% |
对照组 | 50 | 66.3 | 21 | 13 | 16 | 60.2±20.45 | 68.30% |
例数 | 年龄 | 治愈 | 好转 | 无效 | 用时(天) | 总有效率 | |
治疗组 | 55 | 28.4 | 50 | 0 | 5 | 24.3±14.28 | 90.90% |
对照组 | 34 | 27.9 | 19 | 4 | 11 | 35.6±21.22 | 67.64% |
组别 | 例数 | 治愈 | 好转 | 无效 | 平均愈合天数 | 总有效率% |
治疗组 | 160 | 149 | 0 | 11 | 16.8±7.48 | 93.12 |
对照组 | 50 | 23 | 13 | 14 | 28.3±11.00 | 72.00 |
组别 | 例数 | 治愈 | 好转 | 无效 | 平均愈合天数 | 总有效率% |
治疗组 | 180 | 180 | 0 | 0 | 7.8±4.40 | 100 |
对照组 | 30 | 15 | 8 | 7 | 15.9±6.90 | 76.67 |
组别 | 例数 | 治愈 | 好转 | 无效 | 平均愈合天数 | 总有效率% |
治疗组 | 130 | 95 | 30 | 5 | 25.6±8.77 | 96.15 |
对照组 | 30 | 8 | 11 | 11 | 48.7±10.25 | 63.33 |
组别 | 例数 | 治愈 | 好转 | 无效 | 平均愈合天数 | 总有效率% |
治疗组 | 155 | 150 | 0 | 5 | 24.3±14.28 | 96.77 |
对照组 | 34 | 19 | 4 | 11 | 35.6±21.22 | 67.64 |
组别 | 例数 | 治愈 | 好转 | 无效 | 平均愈合天数 | 总有效率% |
治疗组 | 86 | 86 | 0 | 0 | 28.1±4.06 | 100.00 |
对照组 | 30 | 8 | 8 | 14 | 36.4±8.50 | 53.30 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410029549 CN1224417C (zh) | 2004-03-22 | 2004-03-22 | 治疗皮肤损伤的外用药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410029549 CN1224417C (zh) | 2004-03-22 | 2004-03-22 | 治疗皮肤损伤的外用药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539496A true CN1539496A (zh) | 2004-10-27 |
CN1224417C CN1224417C (zh) | 2005-10-26 |
Family
ID=34352229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410029549 Expired - Lifetime CN1224417C (zh) | 2004-03-22 | 2004-03-22 | 治疗皮肤损伤的外用药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1224417C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100448484C (zh) * | 2005-10-31 | 2009-01-07 | 张力元 | 医用射线防护喷剂 |
CN101926825A (zh) * | 2009-06-26 | 2010-12-29 | 杨建伟 | 一种红油膏药品及其配制方法 |
CN107737131A (zh) * | 2017-12-12 | 2018-02-27 | 杨小玉 | 一种皮肤黏膜损伤抑菌消毒剂及制备方法 |
CN110051793A (zh) * | 2019-05-09 | 2019-07-26 | 青岛大学附属医院 | 一种皮肤放射损伤防护剂及其制备方法 |
CN111671885A (zh) * | 2020-06-15 | 2020-09-18 | 中国人民解放军西部战区总医院 | 一种用于治疗放射性皮炎的药物 |
-
2004
- 2004-03-22 CN CN 200410029549 patent/CN1224417C/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100448484C (zh) * | 2005-10-31 | 2009-01-07 | 张力元 | 医用射线防护喷剂 |
CN101926825A (zh) * | 2009-06-26 | 2010-12-29 | 杨建伟 | 一种红油膏药品及其配制方法 |
CN107737131A (zh) * | 2017-12-12 | 2018-02-27 | 杨小玉 | 一种皮肤黏膜损伤抑菌消毒剂及制备方法 |
CN110051793A (zh) * | 2019-05-09 | 2019-07-26 | 青岛大学附属医院 | 一种皮肤放射损伤防护剂及其制备方法 |
CN111671885A (zh) * | 2020-06-15 | 2020-09-18 | 中国人民解放军西部战区总医院 | 一种用于治疗放射性皮炎的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN1224417C (zh) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rashad et al. | Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer | |
CN101829320B (zh) | 一种胶原蛋白凝胶及其制备方法 | |
Bilge et al. | Could ozone treatment be a promising alternative for osteomyelitis? An experimental study | |
CN104306358A (zh) | 止痒祛疤涂膜剂 | |
AU2007241026A1 (en) | Pharmaceutical compositions for promoting wound healing | |
JP2010241786A (ja) | ハチ毒を有効成分とする創傷又は火傷治療用組成物 | |
CN1224417C (zh) | 治疗皮肤损伤的外用药物组合物 | |
CN105148316B (zh) | 一种锌基蒙脱石无菌创可贴及其制备方法和应用 | |
CN105879006A (zh) | 一种治疗糖尿病足溃疡的药物组合物及其制备方法和应用 | |
CN1316965C (zh) | 一种透明、隐形的外用给药载体 | |
CN1201747C (zh) | 含有维生素b12的外用药物组合物 | |
CN1270776C (zh) | 治疗粘膜溃疡的药物组合物,其制备和用途 | |
CN102755414B (zh) | 用于外伤创面的中药药膏及其制备方法 | |
CN1772127A (zh) | 七味解毒活血膏及其制备方法 | |
RU2209074C2 (ru) | Состав для лечения ожогов | |
CN1850202A (zh) | 一种阴道外用药物组合物及其制备方法和用途 | |
CN104739856B (zh) | 蒙脱石外用散剂在制备治疗皮肤溃疡的药物中的应用 | |
CN110559292A (zh) | pifithrin-α在制备放疗辐照后促进皮肤伤口愈合的药物中的应用 | |
CN105213416A (zh) | 一种治疗皮肤粘膜损伤的药物组合物 | |
RU2606834C2 (ru) | Гель-фотосенсибилизатор для фотодинамической терапии | |
CN104758310B (zh) | 复方蒙脱石蔗糖软膏及其制备方法和应用 | |
CN109674743A (zh) | 一种伤口护理凝胶及其制备方法 | |
CN103191163A (zh) | 一种皮肤创面修复药物组合物 | |
Kirschner | CHLOROPHYLL as THERAPY–Cancer–Germs-Intestines | |
US20080038376A1 (en) | Anti-cancer composition and method for using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN AODONG GROUP JINHAIFA PHARMACEUTICAL CO., LT Free format text: FORMER OWNER: JI HUI Effective date: 20120326 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130021 CHANGCHUN, JILIN PROVINCE TO: 133600 YANBIAN KOREAN AUTONOMOUS PREFECTURE, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120326 Address after: 133600 Mingyue County, Jilin, Antu Patentee after: Jilin Aodong Medicine Industry Group Co.,Ltd. Address before: 130021, Xinmin Avenue, Changchun, Jilin, 13 Patentee before: Ji Hui |
|
ASS | Succession or assignment of patent right |
Owner name: YANBIAN MEDICINE INDUSTRY CO LTD, AODONG Free format text: FORMER OWNER: JILIN AODONG GROUP JINHAIFA PHARMACEUTICAL CO., LTD. Effective date: 20140414 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 133600 YANBIAN KOREAN AUTONOMOUS PREFECTURE, JILIN PROVINCE TO: 133700 YANBIAN KOREAN AUTONOMOUS PREFECTURE, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140414 Address after: 133700 Jilin province Aodong Dunhua Street No. 2158 Patentee after: JILIN AODONG YANBIAN PHARMACEUTICAL CO.,LTD. Address before: 133600 Mingyue County, Jilin, Antu Patentee before: Jilin Aodong Medicine Industry Group Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051026 |